Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date01 Oct 1996 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Safety study of NaPPS in pediatric patients with mucopolysaccharidosis type VI
Clinical trial with NaPPS for HTLV-1-associated myelopathy (HAM) patients - Clinical trial with NaPPS for HAM patients
Phase III study combined with post-marketing clinical study of RM1319 in patients with inborn errors of bile acid metabolism, including children - Phase III study combined with post-marketing clinical study of RM1319 in patients with inborn errors of bile acid metabolism, including children
100 Clinical Results associated with ReqMed Co., Ltd.
0 Patents (Medical) associated with ReqMed Co., Ltd.
2018·Seibutsu Kogaku Kaishi
New encounter especially when things were bad
2009·Seibutsu Kogaku Kaishi
Come over Inter-college, Bioseries
Author: Matsumoto, Tadashi
2008·Seibutsu Kogaku Kaishi
Carrer path. Novartis/biocamp: dream, challenge and presure
Author: Matsumoto, Tadashi
100 Deals associated with ReqMed Co., Ltd.
100 Translational Medicine associated with ReqMed Co., Ltd.